Clinical use of indium-111 labeled blood products

M. K. Loken, M. E. Clay, R. T. Carpenter, R. J. Boudreau, J. J. McCullough

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Following the introduction of In-111 oxine as a label for blood cells by McAffee and Thakur in 1976, these procedures have become increasingly important in the practice of nuclear medicine. Of particular interest are studies involving the use of labeled leukocytes for the detection of focal infection. The clincial utility of labeled platelets is less well developed, although the use of platelets to detect the formation of thrombi in blood vessels and on vascular grafts and prostheses is gaining prominence. This report summarizes the techniques presently employed at the University of Minnesota for the labeling of blood products, and their clinical use. Consideration also is given to the desired expertise and cost factors involved in the labeling of leukocytes and platelets.

Original languageEnglish (US)
Pages (from-to)902-911
Number of pages10
JournalClinical Nuclear Medicine
Issue number12
StatePublished - Dec 1 1985


Dive into the research topics of 'Clinical use of indium-111 labeled blood products'. Together they form a unique fingerprint.

Cite this